MX2022004219A - Moduladores de atf6 y usos de los mismos. - Google Patents

Moduladores de atf6 y usos de los mismos.

Info

Publication number
MX2022004219A
MX2022004219A MX2022004219A MX2022004219A MX2022004219A MX 2022004219 A MX2022004219 A MX 2022004219A MX 2022004219 A MX2022004219 A MX 2022004219A MX 2022004219 A MX2022004219 A MX 2022004219A MX 2022004219 A MX2022004219 A MX 2022004219A
Authority
MX
Mexico
Prior art keywords
atf6
modulators
diseases
compounds
treatment
Prior art date
Application number
MX2022004219A
Other languages
English (en)
Inventor
Balaji Dashrath Sathe
Sebastian Bernales
Brahmam Pujala
Díaz Gonzalo Andrés Ureta
Sebastian Belmar
Original Assignee
Praxis Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Biotech LLC filed Critical Praxis Biotech LLC
Publication of MX2022004219A publication Critical patent/MX2022004219A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos como moduladores del Factor 6 de Transcripción de Activación (ATF6). Los compuestos pueden encontrar uso como agentes terapéuticos para el tratamiento de enfermedades o trastornos mediados por ATF6 y pueden encontrar uso particular en el tratamiento de infecciones virales, enfermedades neurodegenerativas, enfermedades vasculares o cáncer.
MX2022004219A 2019-10-09 2020-10-09 Moduladores de atf6 y usos de los mismos. MX2022004219A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913122P 2019-10-09 2019-10-09
US201962913125P 2019-10-09 2019-10-09
PCT/EP2020/078507 WO2021069721A1 (en) 2019-10-09 2020-10-09 Atf6 modulators and uses thereof

Publications (1)

Publication Number Publication Date
MX2022004219A true MX2022004219A (es) 2022-05-18

Family

ID=72895928

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004219A MX2022004219A (es) 2019-10-09 2020-10-09 Moduladores de atf6 y usos de los mismos.

Country Status (12)

Country Link
US (1) US20230028584A1 (es)
EP (1) EP4041728A1 (es)
JP (1) JP2022552235A (es)
KR (1) KR20220087464A (es)
CN (1) CN115087656A (es)
AU (1) AU2020365038A1 (es)
BR (1) BR112022006560A2 (es)
CA (1) CA3157173A1 (es)
CL (1) CL2022000895A1 (es)
IL (1) IL291962A (es)
MX (1) MX2022004219A (es)
WO (1) WO2021069721A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201722958A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
KR20190028540A (ko) * 2016-07-20 2019-03-18 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Perk 억제제로서의 이소퀴놀린 유도체
US10829485B2 (en) * 2018-04-06 2020-11-10 Black Belt Tx Ltd ATF6 inhibitors and uses thereof
EP3784234A1 (en) * 2018-04-25 2021-03-03 Yumanity Therapeutics, Inc. Compounds and uses thereof

Also Published As

Publication number Publication date
IL291962A (en) 2022-06-01
BR112022006560A2 (pt) 2022-06-28
EP4041728A1 (en) 2022-08-17
WO2021069721A1 (en) 2021-04-15
US20230028584A1 (en) 2023-01-26
KR20220087464A (ko) 2022-06-24
AU2020365038A1 (en) 2022-05-19
CN115087656A (zh) 2022-09-20
CL2022000895A1 (es) 2023-01-13
JP2022552235A (ja) 2022-12-15
CA3157173A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
MX2023010326A (es) Inhibidores de atf6 y sus usos.
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
SA518391624B1 (ar) Ror- منظمات جاما
PH12020551425A1 (en) Rimegepant for cgrp related disorders
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2018009257A (es) Derivados de benzimidazol como moduladores de ror-gamma.
AU2018264384A1 (en) Solid forms of berberine ursodeoxycholate and compositions and methods thereof
MX2023002507A (es) Inhibidores de cd73.
PH12021550872A1 (en) Therapeutic compounds
PH12021550443A1 (en) Pyridazinones and methods of use thereof
JO3789B1 (ar) التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
MX2022005256A (es) Inhibidores de cd73.
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
AU2018320418A1 (en) Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
EP4364805A3 (en) Novel pyridazines
PH12020551772A1 (en) Oxo-substituted compound
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MX2021004860A (es) Piridazinas novedosas.
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
AU2018320416A8 (en) Pyridylpyridone compounds
MX2022004212A (es) Moduladores de atf6 y usos de los mismos.
MX2021011081A (es) Derivados de nicorandil.
WO2019209232A3 (en) The use of terpenic coumarine derivative molecules in the treatment of cancer disease